CompletedPhase 1NCT00402766
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Anne S. Tsao, MDM.D. Anderson Cancer Center
- Intervention
- Cisplatin(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2014
Study locations (1)
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00402766 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGPHASE2NCT06543069Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT06581549Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCS
- RECRUITINGPHASE2NCT06057935A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaMemorial Sloan Kettering Cancer Center